NCT01387763 - A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms | Biotech Hunter

Enrollment

202

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions

Polycythemia VeraEssential ThrombocythemiaPrimary Myelofibrosis

Interventions

DRUG

PegIntron

PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.

DRUG

Pegasys

Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly

DRUG

PegIntron

PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.

DRUG

Pegasys

Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly

DRUG

Hydrea

Capsule Hydrea 500-2000 mg orally QD or BID

Trial Locations (8)

2100

Dept of Hematology, Rigshospitalet, Copenhagen

2730

Dept of Hematology, Herlev Hospital, Herlev

4000

Dept. of Hematology, Roskilde Hospital, Roskilde

5000

Dept of hematology, Odense University Hospital, Odense

6700

Dept of Hematology, Esbjerg Hospital, Esbjerg

7500

Dept of Hematology, Holstebro Hospital, Holstebro

8000

Dept. of Hematology, Aarhus University Hospital, Aarhus

9000

Dept of Hematology, Aalborg hospital, Aalborg

All Listed Sponsors

lead

Thomas Stauffer Larsen

OTHER